Pilot Study: Effects of Nimodipine on Alcohol Drinking
Key facts
- Who runs it
- Yale University
- Where
- New Haven, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 5 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 30 Jun 2032
- Type of study
- Interventional
- Treatments tested
- Nimodipine
- Record updated
- 17 March 2026
Who can take part
- Age
- 21 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (23)Hide the full registry criteria
Who can take part
- Ages 21-50 (The lower limit is to avoid offering alcohol to individuals below the drinking age of 21. The upper age is determined by experience recruiting for our prior studies)
- Ability to read English at 6th grade level or higher
- Meet DSM-V criteria for at least moderate AUD
- Average weekly alcohol consumption of 30-70 standard drinks for men and 20-65 drinks for women. The lower limits are consistent with the lower sex-specific cut-offs defining high-risk drinking based on World Health Organization Risk Levels (WHO, 2000); the upper limits are designed to avoid recruiting participants whose drinking is likely to exceed the number of drinks available in the alcohol drinking paradigm (ADP)
Who cannot take part
- Positive urine drug screens at more than 1 baseline appointment for opiates, cocaine, benzodiazepines, and barbiturates
- Regular use of psychoactive drugs, except for individuals on a stable dose of an antidepressant for at least 2 months
- Participants who refuse to use a reliable method of birth control from the time of first medication administration to 7 days after. These include oral contraceptives, contraceptive sponge, patch, double barrier (diaphragm/spermicidal or condom/spermicidal), intrauterine contraceptive system, etonogestrel implant, medroxyprogesterone acetate contraceptive injection, complete abstinence from sexual intercourse, hormonal vaginal contraceptive ring, surgical sterilization, or true abstinence
- Subjects who have taken any investigational drug within 4 weeks of the anticipated date of the first study dose
- Individuals who report heavy drinking days in the 2 days prior to their intake appointment but have a negative ethyl glucuronide (EtG) test to rule out subjects who are misrepresenting their drinking history
- Meet current DSM-V criteria for substance use disorder, except for tobacco use disorder or mild cannabis use disorder
- Psychotic or other severe psychiatric disorders as determined by clinical evaluation
- Medical conditions that would contraindicate the consumption of alcohol or use of nimodipine including untreated or not adequately controlled hypertension or hypotension. Blood pressure at or below 100/65 will be exclusionary
- Heart rate of less than 50 bpm
- Neurological trauma or disease, delirium, or hallucinations, or clinically significant or unstable medical conditions, including uncontrolled hypertension or diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic diseases, which in the opinion of the study physician and PI, may put the patient at risk because of participation in the study
- Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) scores of 8 or greater or a history of significant repeated alcohol withdrawals to reduce the likelihood of withdrawal symptomatology if subjects reduce their drinking
- Heart rate of less than 50 bpm
- Clinically significant abnormalities in screening laboratories, including aspartate aminotransferase (AST) >3 times upper limit of normal (ULN); alanine aminotransferase (ALT) > 3 times ULN; total bilirubin >1.5 times ULN; serum creatinine >2.0 times ULN
- Concurrent use of the following medications: CYP3A4 inhibitors and inducers, other calcium channel blockers, or other blood pressure lowering medications
- Individuals who are seeking alcohol treatment or have been in alcohol treatment within the past 6 months
- Women who are pregnant or nursing
- Subjects who report disliking spirits will be excluded because hard liquor will be provided during the ADP
- Subjects who have donated blood within the past 6 weeks
- Subjects with a history or presence of cirrhosis
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Alcohol use disorder
Where in United States
- Yale University School of Medicine, Connecticut Mental Health CenterNew Haven, United StatesContact: Thomas LissNot yet recruiting
About the trial
What the trial wants to find out
This is an open label trial aiming to recruit 5 non-treatment seeking adults with Alcohol Use Disorder. All will participate in an alcohol drinking paradigm (ADP) lab session at the Hospital Research Unit (HRU) at Yale-New Haven Hospital (YNHH). Participants will stay overnight and receive nimodipine 90 mg/dose every six hours during an 18-hour period prior to the ADP to allow for the limited central nervous system bioavailability of this drug. Electroencephalogram (EEG) data will be collected before the first dose and after the last dose of nimodipine. Adverse events will be closely monitored during this period. During the ADP session participants will receive a priming dose of alcohol followed by a one-hour monitoring period. This will be followed by three one-hour self-administration periods; during each hour, participants will be able to choose between drinking up to four drinks or receive the monetary equivalents of these drinks (total of 12 drinks over three hours).
The group in the trial
- NimodipineTreatment being tested
All participants will be assigned to this arm and will receive study drug (nimodipine), open label.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Study on the Effects of Nimodipine on Alcohol Drinking Among Adults Who Are Heavy Alcohol Drinkers
- Criteria questions
- Built from NCT06900998, who can take part
- Record updated
- 17 March 2026